MES-SA Cells

MES-SA is a human uterine sarcoma cell line derived from the pleural effusion of an adult patient with high-grade uterine leiomyosarcoma. As a model of soft tissue sarcoma, MES-SA displays characteristics of mesenchymal origin, including spindle-shaped morphology and smooth muscle actin expression. Cytogenetic analysis of MES-SA reveals complex karyotypic abnormalities, including multiple numerical and structural chromosomal alterations. Importantly, this cell line is widely used in studies of multidrug resistance and chemotherapy response, due to its documented sensitivity to doxorubicin and the availability of its drug-resistant subline, MES-SA/Dx5.

MES-SA exhibits wild-type p53 and retinoblastoma protein (Rb), making it a useful tool for studying drug responses in p53-competent backgrounds. In various functional genomics and proteomics screens, MES-SA has demonstrated consistent patterns of signal transduction pathway engagement, particularly those involving PI3K/Akt and MAPK pathways. Reverse-phase protein array profiling has confirmed the activity of these pathways and revealed protein expression signatures relevant to targeted therapy exploration. Moreover, the cell line is included in large-scale pharmacogenomic resources such as the Cancer Cell Line Encyclopedia, where it has been utilized for integrative analyses of drug sensitivity, genetic dependencies, and epigenetic modifications.

Recent investigations into chromatin state and gene regulation in MES-SA have highlighted epigenetic vulnerabilities, particularly involving promoter methylation and histone modification patterns. MES-SA serves as a model system in studies of histone deacetylase inhibitors and agents targeting chromatin modifiers. Its inclusion in both reverse-phase protein array and DNA methylation databases further enhances its relevance in preclinical drug development, especially for sarcoma-focused therapeutics. Collectively, MES-SA provides a robust and well-characterized platform for investigating the molecular underpinnings of uterine sarcomas and for evaluating therapeutic strategies targeting mesenchymal tumors.